Transfusion Using Stored Whole Blood

Trauma Clinical Trial

Official title:

Transfusion of Stored Whole Blood in a Civilian Trauma Center: A Prospective Evaluation of Feasibility and Outcomes

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02926274
• Other study ID #: NTI-JWMRP-201501
• Status: Active, not recruiting
• Phase: N/A
• First received: August 29, 2016
• Last updated: October 24, 2017
• Start date: October 18, 2017
• Est. completion date: October 2019

Study information

• Verified date: October 2017
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Massive hemorrhage is a major cause of potentially preventable death following trauma. A common consequence of hemorrhagic shock is uncontrollable bleeding from coagulopathy, leading to death from exsanguination. Even when bleeding is controlled, patients are at increased risk of complications and mortality. Reconstituted whole blood, or component therapy with packed red blood cells (PRBCs), plasma, and platelets was introduced by the military in recent conflicts in Iraq and Afghanistan with remarkable results and has been adopted by most civilian trauma centers. Despite improving coagulopathy, it is apparent that transfusion of blood components is not equivalent to whole blood transfusion. Transfusion of high plasma volumes may be associated with increased risk of allergic reaction, transfusion associated acute lung injury (TRALI), hypervolemic cardiac failure, and acute respiratory distress syndrome (ARDS). Military services have recently reintroduced fresh whole blood (WB) for standard resuscitation of massive hemorrhage, have found that WB offers a survival advantage over component therapy, and that risks of transfusion reactions are similar for WB and PRBCs. On the civilian side, whole blood is an FDA-licensed product that has been in use in pediatric open heart surgery and autologous blood donation but is no longer commonly available for other indications. However, the military results are renewing interest in whole blood for trauma resuscitation. The use of low-antibody titer whole blood leukoreduced with a platelet-sparing filter was recently approved by the University of California Los Angeles Blood and Blood Derivatives Committee and two other trauma centers for male trauma patients. This study will test the feasibility of providing stored WB for resuscitation of patients in hemorrhagic shock and determine the effects of WB on clinical outcomes as well as the effects on coagulation, fibrinolysis, and inflammation, compared to standard blood component therapy.

Description:

Most current massive transfusion protocols attempt to treat the early coagulopathic state induced by severe injury and hemorrhagic shock with transfusion of red blood cells, plasma, and platelets in a 1:1:1 ratio replicating whole blood. Civilian trauma centers have now begun to initiate resuscitation of adult male patients with stored whole blood as a standard of care, however.

The main hypothesis behind this change in practice is that transfusion of whole blood (WB) rather than attempted reconstitution from its banked components is safer, more efficient and effective treatment of hemorrhagic shock following injury and will result in less frequent development of clinical coagulopathy and subsequent mortality. Whole blood offers the advantages of more precisely approximating shed blood; decreased volume of additives per unit; and exposure to a decreased number of donors for a patient undergoing massive transfusion. It remains to be seen whether this will translate into differences in coagulopathy, inflammation, and mortality. The purpose of this study is to investigate the feasibility of developing a system to collect, store, and deliver whole blood for trauma resuscitations in a civilian trauma center.

The universal donor blood type for patients with unknown blood type is type O positive blood for males and O negative for females. Because O negative blood is rare the study will initiate the change in practice in adult male patients and later extend it to female patients if feasible. The study will determine the effects of WB transfusion in adult male patients compared to transfusion of PRBCS, plasma, and platelets in a 1:1:1 ratio in non adult male patients on markers of coagulation, fibrinolysis, and inflammation, as well as the development of complications and hospital mortality following severe injury.

Specific aims are to:

1. Determine the appropriate shelf life of WB that has been leukoreduced with a platelet sparing filter by measuring changes in levels of coagulation factors and global clotting potential of banked units over time. To accomplish this the investigators will measure variables known to reflect potential and actual clotting capacity including platelet function and overall clotting ability by thromboelastography (TEG) and thrombin generation analysis in whole blood up to 35 days.

2. Prospectively determine the effectiveness of trauma resuscitation using WB compared to component therapy and its effects on variables known to reflect potential and actual clotting capacity including markers of coagulation, fibrinolysis, inflammation, platelet function and global hemostatic potential post transfusion, as well as hospital outcomes including development of coagulopathy, infection, venous thromboembolism (VTE), multiple organ failure (MOF), total transfusion requirements, and mortality.

3. Test the feasibility and implementation of a system to provide WB for resuscitation of trauma patients in hemorrhagic shock in civilian trauma centers. This will be accomplished by monitoring cost, storage needs, frequency of blood collection, number of donors, inventory, utilization and wastage of unused units.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 98
• Est. completion date: October 2019
• Est. primary completion date: October 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All adult trauma patients presenting to Ronald Reagan University of California Los Angeles (UCLA) Medical Center with systolic blood pressure <100 suspected due to hemorrhage are eligible. Adult males will receive whole blood when available. Adult female patients will receive component therapy.

Exclusion Criteria:

• Burn patients, patients with medical bracelets or other directives refusing blood transfusion if known during emergent resuscitation for traumatic injury, pediatric patients

Related Conditions & MeSH terms

• Blood Coagulation Disorders
• Coagulopathy
• Hemorrhage
• Hemostatic Disorders
• Trauma
• Wounds and Injuries

Locations

Country	Name	City	State
United States	Ronald Reagan UCLA Medical Center	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Volume of blood products transfused during resuscitation	Volume of blood products transfused (whole blood, packed red blood cells, platelets, and plasma) within the first 24 hours of admission.	From admission to 24 hours after admission
Secondary	mortality		Mortality at 30 days after injury
Secondary	platelet mapping by thromboelastography	Platelet mapping determines the degree of inhibition of platelet function, measured on blood samples from patients being resuscitated during hemorrhagic shock. The primary outcome is the sample taken immediately following transfusion of 6 units of whole blood or packed red blood cells during initial resuscitation (almost always within one day of injury); or, if less than 6 units are transfused before hemostasis is achieved, immediately after transfusion of the last unit (within one day after injury).	within one day of injury, after 6 units of whole blood or packed red blood cell transfusion, or after hemostasis is achieved if less than 6 units are required
Secondary	Thromboelastography reaction time	Determines the time to first evidence of clot formation, measured on blood samples from patients being resuscitated during hemorrhagic shock. The primary outcome is the sample taken immediately following transfusion of 6 units of whole blood or packed red blood cells during initial resuscitation (almost always within one day of injury); or, if less than 6 units are transfused before hemostasis is achieved, immediately after transfusion of the last unit (within one day after injury).	within one day of injury, after 6 units of whole blood or packed red blood cell transfusion, or after hemostasis is achieved if less than 6 units are required
Secondary	Thromboelastography K value	Determines the time from first evidence of clot formation to the time the clot reaches a diameter of 20mm, thus representing the rate of clot formation. This will be measured on blood samples from patients being resuscitated during hemorrhagic shock. The primary outcome is the sample taken immediately following transfusion of 6 units of whole blood or packed red blood cells during initial resuscitation (almost always within one day of injury); or, if less than 6 units are transfused before hemostasis is achieved, immediately after transfusion of the last unit (within one day after injury).	within one day of injury, after 6 units of whole blood or packed red blood cell transfusion, or after hemostasis is achieved if less than 6 units are required
Secondary	Thromboelastography maximum amplitude (MA)	Maximum amplitude is a measure of overall clot strength measured on blood samples from patients being resuscitated during hemorrhagic shock. The primary outcome is the sample taken immediately following transfusion of 6 units of whole blood or packed red blood cells during initial resuscitation (almost always within one day of injury); or, if less than 6 units are transfused before hemostasis is achieved, immediately after transfusion of the last unit (within one day after injury).	within one day of injury, after 6 units of whole blood or packed red blood cell transfusion, or after hemostasis is achieved if less than 6 units are required
Secondary	total units of blood products transfused (includes whole blood, packed red blood cells, plasma, platelets, and cryoprecipitate).		3 and 6 hours after admission, 24 hours after admission, and total for hospital stay within 30 days of injury
Secondary	venous thromboembolism		any venous thromboembolism occurring during hospitalization within 30 days of injury.
Secondary	infection (documentation of suspected or confirmed infection in the medical chart including urinary tract infection, pneumonia, wound infection, infectious colitis, and bacteremia).		during hospitalization within 30 days of injury.
Secondary	Development of clinical coagulopathy	Documentation of diffuse clinical bleeding or documented clinical coagulopathy based on laboratory evidence by the primary team	Within 24 hours of injury, and during hospitalization within 30 days
Secondary	Development of Acute Respiratory Distress Syndrome		During hospitalization within 30 days
Secondary	Development of acute kidney injury requiring renal replacement therapy		During hospitalization within 30 days
Secondary	Hemolysis	7. Hemolysis as measured by haptoglobin, bilirubin, lactate dehydrogenase, and direct antiglobulin	within 24 hours of admission
Secondary	cerebrovascular accident		During hospitalization within 30 days
Secondary	acute coronary syndrome		During hospitalization within 30 days
Secondary	transfusion-related lung injury		During hospitalization within 30 days
Secondary	transfusion-associated cardiac overload		During hospitalization within 30 days
Secondary	Duration of need for renal replacement therapy		During hospitalization within 30 days
Secondary	Duration of need for mechanical ventilation		During hospitalization within 30 days
Secondary	Duration ICU admission		During hospitalization
Secondary	Duration hospital admission		During hospitalization